In looking at the locations this is offered in some not so common areas i.e. in Conn at Yale --
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
https://clinicaltrials.gov/ct2/show/study/NCT02335918#contacts
No comments:
Post a Comment